Correction to: Scientific Reports https://doi.org/10.1038/s41598-021-91589-2, published online 08 June 2021
The original version of this Article contained errors in the horizontal axis label of Figure 3. As a result,
"6 months, 9 months, and 12 months"
now reads:
"12 months, 24 months, and 36 months".
The original Figure 3 and accompanying legend appear below.
Changes in mean central foveal thickness during the 36-month anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy (PNV), polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1), and typical neovascular age-related macular degeneration (nAMD). The mean central foveal thickness showed a significant decrease when comparing from baseline through the 36 months follow-up for the groups. However, there was no significant difference between the groups in central foveal thickness at 3, 12, 24, and 36 months.
The original Article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Yoon, J., Yoon, W., Na, S. et al. Author Correction: Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci Rep 11, 18647 (2021). https://doi.org/10.1038/s41598-021-98358-1
Published:
Version of record:
DOI: https://doi.org/10.1038/s41598-021-98358-1
